Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
Volume 1.58M
Average 1.61M
AVTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Avalo Therapeutics, Inc.NASDAQ: AVTX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows in line with its trailing trend
Q1 FY2026 selling, general & admin of $6.84M rose 23.3% year over year, in line with the +23.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 4.6% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- Selling, general & admin amounted to 38813.6% of revenue in FY2025, up 34904.0 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 12 analysts of $87.66M (+282.8%) for the fiscal year ending Dec 2026, a step up from the +32.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.84M+4.6% QoQ
- Last fiscal yearDec 2025
- $22.9M+32.8% YoY
- LTMMar 2026
- $24.19M+23.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 22.9M USD
- Year-over-year change
- +32.8%
- 4-year CAGR
- -1.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.9M | +32.8% |
| FY2024 | 2024-12-31 | 17.24M | +67.4% |
| FY2023 | 2023-12-31 | 10.3M | -50.3% |
| FY2022 | 2022-12-31 | 20.71M | -16.0% |
| FY2021 | 2021-12-31 | 24.66M | — |
Selling, General & Admin vs competitors
How AVTX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.5% is the 5th highest of 10, against a peer median of +5.5%.
- Selling, general & admin amounts to 41000.0% of revenue for AVTX, versus a peer median of 64.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.29M USD | +5.1% | +10.3% | 62.2% | |
| LTM Mar 2026 | $62.81M USD | +42.2% | +11.5% | 27.0% | |
| LTM Sep 2026 | $60.45M USD | +31.0% | +18.9% | 66.8% | |
| LTM Mar 2026 | $24.19M USD | +23.5% | +3.4% | 41000.0% | |
| LTM Mar 2026 | $23.53M USD | +30.1% | +11.7% | — | |
| LTM Mar 2026 | $22.58M USD | +5.5% | -4.4% | 269.8% | |
| LTM Mar 2026 | $17.08M USD | -4.8% | +20.7% | 31.8% | |
| LTM Mar 2026 | $16.54M USD | -15.6% | +10.2% | — | |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €9.82M EUR | +63.8% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AVTX) | — | +5.5% | +10.9% | 64.5% | |
Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.4M | 18.05M | 1.92M | 441K | 59K |
| Cost of Revenue | 1.49M | 3.43M | 1.28M | (366K) | 0 |
| Gross Profit | 3.91M | 14.62M | 640K | 807K | 59K |
| Gross Margin | 72.4% | 81.0% | 33.3% | 183.0% | 100.0% |
| Research & Development | 59.84M | 31.31M | 13.78M | 52.08M | 50.08M |
| Selling, General & Admin | 24.66M | 20.71M | 10.3M | 17.24M | 22.9M |
| Operating Expenses | 86.04M | 52.06M | 27.99M | 69.32M | 72.98M |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| EBITDA | (80.5M) | (37.29M) | (23.29M) | (34.85M) | (77.75M) |
| EBITDA Margin | -1491.2% | -206.6% | -1210.3% | -7901.6% | -131779.7% |
| Operating Income | (82.13M) | (37.44M) | (27.35M) | (68.51M) | (72.93M) |
| Operating Margin | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Interest Income | 0 | 0 | 0 | 3.32M | 4.35M |
| Interest Expense | 2.39M | 4.17M | 3.42M | 0 | 0 |
| Other Income / Expenses | (2.41M) | (4.19M) | (4.18M) | 33.5M | (5.17M) |
| Income Before Tax | (84.55M) | (41.63M) | (31.53M) | (35.02M) | (78.09M) |
| Pre-Tax Margin | -1566.2% | -230.6% | -1638.8% | -7939.9% | -132362.7% |
| Income Tax Expense | (196K) | 28K | 14K | 114K | 165K |
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Net Margin | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| EPS (Basic) | (2,330.66) | (1,062.65) | (113.58) | (4.32) | (5.84) |
| EPS (Diluted) | (2,330.66) | (1,062.65) | (113.58) | (3.26) | (5.84) |
| Weighted Avg Shares | 36.19K | 39.2K | 277.73K | 8.13M | 13.4M |
| Weighted Avg Shares (Diluted) | 36.19K | 39.2K | 277.73K | 10.78M | 13.4M |
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.